Effect of pitavastatin treatment on ApoB-48 and Lp-PLA2 in patients with metabolic syndrome

Substudy of prospective comparative clinical study evaluating the efficacy and safety of pitavastatin in patients with metabolic syndrome

PROPIT Study Team

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA2 levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study. Methods: We enrolled 75 patients with MS from the PROPIT study and randomized them into two treatment groups: 2 mg pitavastatin daily+intensive LSM or intensive LSM only. We measured the change of lipid profiles, ApoB-48 and Lp-PLA2 for 48 weeks. Results: Total cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (P ≤ 0.001). Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. The change in Lp-PLA2 was not significant after intervention in either group after treatment with pitavastatin for 1 year. Conclusion: Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels.

Original languageEnglish
Pages (from-to)120-126
Number of pages7
JournalEndocrinology and Metabolism
Volume31
Issue number1
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Apolipoprotein B-48
Life Style
Safety
Apolipoprotein B-100
Cardiovascular Diseases
Therapeutics
Lipids
Clinical Studies
pitavastatin
LDL Cholesterol
Lipoproteins
Blood Vessels
Cholesterol
Prospective Studies

Keywords

  • Apolipoprotein B-48
  • Lp-PLA
  • Metabolic syndrome
  • Pitavastatin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{d4fdc2580a184879aec4dddc8a82aac2,
title = "Effect of pitavastatin treatment on ApoB-48 and Lp-PLA2 in patients with metabolic syndrome: Substudy of prospective comparative clinical study evaluating the efficacy and safety of pitavastatin in patients with metabolic syndrome",
abstract = "Background: Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA2 levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study. Methods: We enrolled 75 patients with MS from the PROPIT study and randomized them into two treatment groups: 2 mg pitavastatin daily+intensive LSM or intensive LSM only. We measured the change of lipid profiles, ApoB-48 and Lp-PLA2 for 48 weeks. Results: Total cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (P ≤ 0.001). Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. The change in Lp-PLA2 was not significant after intervention in either group after treatment with pitavastatin for 1 year. Conclusion: Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels.",
keywords = "Apolipoprotein B-48, Lp-PLA, Metabolic syndrome, Pitavastatin",
author = "{PROPIT Study Team} and Lee, {Hyo Sun} and Jung, {Chang Hee} and Kim, {Sung Rae} and Jang, {Hak Chul} and Park, {Cheol Young} and Choi, {Sung Hee} and Soo Lim and Seo, {Ji A} and Noh, {Jung Hyun} and Mok, {Ji Oh} and Lee, {Ki Young} and Park, {Jong Sook} and Kim, {Dae Jung} and Lee, {Chang Beom}",
year = "2016",
month = "3",
day = "1",
doi = "10.3803/EnM.2016.31.1.120",
language = "English",
volume = "31",
pages = "120--126",
journal = "Endocrinology and Metabolism",
issn = "2093-596X",
publisher = "Korean Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Effect of pitavastatin treatment on ApoB-48 and Lp-PLA2 in patients with metabolic syndrome

T2 - Substudy of prospective comparative clinical study evaluating the efficacy and safety of pitavastatin in patients with metabolic syndrome

AU - PROPIT Study Team

AU - Lee, Hyo Sun

AU - Jung, Chang Hee

AU - Kim, Sung Rae

AU - Jang, Hak Chul

AU - Park, Cheol Young

AU - Choi, Sung Hee

AU - Lim, Soo

AU - Seo, Ji A

AU - Noh, Jung Hyun

AU - Mok, Ji Oh

AU - Lee, Ki Young

AU - Park, Jong Sook

AU - Kim, Dae Jung

AU - Lee, Chang Beom

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background: Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA2 levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study. Methods: We enrolled 75 patients with MS from the PROPIT study and randomized them into two treatment groups: 2 mg pitavastatin daily+intensive LSM or intensive LSM only. We measured the change of lipid profiles, ApoB-48 and Lp-PLA2 for 48 weeks. Results: Total cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (P ≤ 0.001). Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. The change in Lp-PLA2 was not significant after intervention in either group after treatment with pitavastatin for 1 year. Conclusion: Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels.

AB - Background: Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA2 levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study. Methods: We enrolled 75 patients with MS from the PROPIT study and randomized them into two treatment groups: 2 mg pitavastatin daily+intensive LSM or intensive LSM only. We measured the change of lipid profiles, ApoB-48 and Lp-PLA2 for 48 weeks. Results: Total cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (P ≤ 0.001). Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. The change in Lp-PLA2 was not significant after intervention in either group after treatment with pitavastatin for 1 year. Conclusion: Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels.

KW - Apolipoprotein B-48

KW - Lp-PLA

KW - Metabolic syndrome

KW - Pitavastatin

UR - http://www.scopus.com/inward/record.url?scp=84962628496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962628496&partnerID=8YFLogxK

U2 - 10.3803/EnM.2016.31.1.120

DO - 10.3803/EnM.2016.31.1.120

M3 - Article

VL - 31

SP - 120

EP - 126

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 2093-596X

IS - 1

ER -